検索結果

At the CIRSE 2025 (Cardiovascular and Interventional Radiological Society of Europe)　international conference in Barcelona, Spain, from September 13-17, 2025, Dr. Shunto Maegawa, our company’s Director &, will present a poster. The poster will highlight the preclinical results of the BioStealth™, a hybrid drug-eluting stent technology for vascular interventions that is currently under development, as well as the protocol of its ongoing pivotal clinical trial. Presentation Information Presentation Number: P-0843 Title: Preclinical Results of a Novel Hybrid Drug-Eluting Stent for Below-the-Knee Arteries and Its Ongoing Pivotal Clinical Trial Protocol: "BioStealth" Stent Technology Presentation Format: Poster presentation (to be displayed in the poster hall during the conference) CIRSE is a globally recognized interventional radiology congress where researchers and clinicians gather to share the latest advancements. This congress provides an opportunity to disseminate our research findings broadly and foster greater understanding among healthcare professionals. Event Overview Title: CIRSE 2025 Dates: September 13–17, 2025 (local time) Venue: Barcelona International Convention Centre (CCIB), Barcelona Organizer: Cardiovascular and Interventional Radiological Society of Europe URL: https://cirse2025.cirse.org/ © CIRSE 2025 / Source: CIRSE Congress promo material

Global Vascular Co., Ltd. (Headquarters: Tokyo, Japan), a company developing a next-generation medical device specializing in the treatment of Peripheral Artery Disease (PAD) in the legs, has successfully raised a total of 1 billion yen in Series B funding. With this round, the company has raised a cumulative total of 2.77 billion yen since its founding. Investors in this round include Diamond Medino Capital Co., Ltd., Mitsubishi UFJ Capital Co., Ltd., Sumitomo Mitsui Trust Bank, Limited, MITSUI SUMITOMO INSURANCE Venture Capital Co., Ltd., Medikit Co., Ltd., Fast Track Initiative, Inc., Tokyo University of Science Innovation Capital Co., Ltd., and Tokyo University of Science Investment Management Co., Ltd., among others. [About Global Vascular] Global Vascular Co., Ltd. is a deep tech startup that originated from a university-based medical engineering collaboration group. The company's mission is "Towards a Future Where Walking is Guaranteed." Led by representative directors Kenta Bito, Ph.D., and Shunto Maegawa, Ph.D., Global Vascular is dedicated to developing the world's first cutting-edge endovascular treatment (EVT) with a proprietary drug-eluting stent delivery system incorporating a uniquely biocompatible material. [Press Release on PR TIMES | June 30, 2025] https://prtimes.jp/main/html/rd/p/000000006.000121727.html For inquiries concerning this matter, please contact us via the form provided below: https://www.g-vasc.com/en/contact

Global Vascular Co., Ltd. is pleased to announce the appointment of Ryutaro Iwanami as External Auditor, effective June 17, 2025. His appointment will further support our efforts to enhance corporate value and reinforce governance as we pursue our mission of "delivering the latest treatments to patients as quickly as possible." Career & Professional Experience  Passed the CPA exam and joined a major audit firm, working primarily on audits and advisory services for globally expanding financial institutions Assigned to the firm’s New York office (2007–2008)  Upon returning to Japan, served as Senior Manager, leading domestic and international audit teams Led audit teams as Executive Officer at a venture company, overseeing both internal audit operations and cross-functional collaboration  Established Iwanami CPA Office in 2015, serving as Representative  Founded Iplus Advisory Co., Ltd. in 2016, serving as President & CEO  Currently engaged in advisory services in financial accounting, managerial accounting, and business management  Qualifications   Certified Public Accountant Licensed Tax Accountant

The 31st Annual Meeting of the Japanese Society for Endovascular Intervention was held on June 13–14, 2025, at the Okinawa Convention Center. Prof. Hasebe, Director of Global Vascular and Professor at Tokai University Hachioji Hospital, served as the meeting chair. This multidisciplinary conference brought together physicians and healthcare professionals from neurosurgery, cardiac and vascular surgery, and radiology. The event aimed to promote the exchange of knowledge and ideas and to foster professional relationships across disciplines, all under the shared theme of “Endovascular Intervention.”   Throughout the two-day program, sessions included presentations on surgical techniques from clinical settings, updates on the latest technologies and research, and a pitch event featuring medical startups, university hospitals, and investors. A live surgical broadcast was also held from Tokai University Hachioji Hospital, where Prof. Hasebe is based, providing real-time footage and expert commentary on operative procedures. Each session saw strong attendance over both days, contributing to a highly productive and meaningful academic meeting. The conference also featured two special guest lectures, including one delivered by our Scientific Advisor, Prof. Elazer R. Edelman. Special Lecture: • Elazer R. Edelman, M.D., Ph.D. (MIT / Harvard Medical School): “The Integration of Basic Science, Engineering and Clinical Insights on an International Scale Propel Biomedical Translational Research” • Rami Tzafriri, Ph.D. (CBSET, Inc.): “Neurovascular thrombectomy – CBSET’s use of autologous clot models to assess efficacy and chronic safety” Global Vascular took part in the corporate exhibition area as a startup in the field of endovascular intervention. For more details, please visit the official conference website: https://n-practice.co.jp/JSEI2025/index.html

The 31st annual meeting of the Japanese Society of Endovascular Intervention, chaired by our company’s director, Professor Hasebe, will take place at the Okinawa Convention Center from June 13 to 14, 2025. In addition to symposiums, presentations and live operation courses, this academic conference will also feature a pitch event that brings startup companies together with current investors and capitalists. Global Vascular will be exhibiting as one of the startups. Dates: June 13 - 14, 2025. Registration period: March 3 - June 14, 2025 Venue: Okinawa Convention Center (4-3-1 Mashiki, Ginowan City, Okinawa Prefecture) Chairman: Professor Terumitsu Hasebe (Department of Diagnostic Radiology/ Endovascular Intervention Center, Tokai University Hachioji Hospital) For further details, please see the annual meeting website below. https://n-practice.co.jp/JSEI2025/index.html

On February 14 ,2025, Ms. Naoko Ishihara was appointed as an outside auditor of our company. As an attorney-at-law, Ms. Ishihara has extensive experience and a proven track record in a wide range of fields, including intellectual property, M&A, startup support, venture capital investment, corporate law including intellectual property strategy and strategic business alliances, cross-border transactions, and dispute resolution. With Ms. Ishihara's appointment, the company will work to further improve its corporate value and strengthen its governance structure in order to achieve its mission of "delivering the latest treatments to patients as quickly as possible." We would like to thank you for your continued support in the future.

Dr. Matsuoka and Dr. Hasebe will be speaking at TCT 2024, the world's largest cardiovascular congress to be held October 27-30, 2024 (Washington, DC local time), to present the latest data on the stent delivery system under development. Sunday, October 27, 9:00 – 10:00AM Moderated Abstracts, Critical Limb Threatening Ischemia - 1 Pre-Clinical Data on a Novel Hybrid Drug-Eluting Stent with Nanocoating for Below-the-Knee Lesions: “Leave the Right Thing Behind” / Emi Matsuoka Kearon Wednesday, October 30, 11:00 – 11:30AM Moderated Abstracts, Peripheral Arterial and Venous Disease and Intervention - 4 The Novel Hybrid Nano-coating Ni-Ti stent for below-the-knee atherosclerotic disease: The Newest “Leave the Right Thing Behind” Concept / Terumitsu Hasebe https://tct2024.crfconferences.com/

The NAM-HLGC is a three-phase grant program that encourages innovation and scientific advances and breakthroughs that extend healthy life expectancy. The first phase, “Catalyst Phase,” is for new ideas that will contribute to extending healthy life expectancy. Our research was awarded 2024 Catalyst Phase. https://healthylongevitychallenge.org/winners/development-of-a-hybrid-nano-coated-nitinol-drug-eluting-stent-hybrid-des-for-small-atherosclerotic-lesions-in-below-the-knee-btk/

Dr. Hasebe, took the stage at CIRSE2024, the annual congress of the Cardiovascular and Interventional Radiological Society of Europe, held from September 14 to 18, 2024 (Lisbon local time), to present on the latest development of our stent delivery system under development. Lecture Session: SP 476 – Peripheral and renal artery 2 September 16, 2024 Current developments on hybrid nano-coated ultrathin-Nitinol drug-eluting stents for below-the-knee atherosclerotic disease: embracing the 'Leave the Right Thing Behind' concept / Terumitsu Hasebe Poster Session: Impact of Combination of “Passive” and “Active” Coating for Below-the-knee Stents: Non-clinical Update of Hybrid Nano-coated Nitinol Drug-eluting Stent (Hybrid-DES) for Below-the-knee Atherosclerotic Disease / Terumitsu Hasebe https://programme.cirse2024.cirse.org/speakers/55561

Emi Matsuoka, COO of Global vascular was invited to speak at the first “Ph.D. Career Talk Series” event held by Blockbuster TOKYO, a program launched in fiscal 2018 by the Tokyo Metropolitan Government to support the development of drug discovery and medical startups in order to realize “Tokyo, the world's number one startup city. https://www.link-j.org/bbt/event/post-8702.html

Dr. Hasebe, took the stage at EuroPCR2024 and PCR Innovators Day, the world's leading academic conference in the field of catheterization in cardiovascular diseases, held from May 13 to 17, 2024 (Paris local time), to present the latest data on the stent delivery system under development. The latest data of the stent delivery system under development was presented.   May 13, Monday CEST　 E-Posters - PCR Innovator's Day 2024 update on the impact of a hybrid nano-coated nitinol drug-eluting stent (hybrid-DES) for BTK / Terumitsu Hasebe May 15, Wednesday /  14:45 – 16:15 CEST　 Innovations for lower limb revascularisation Moderators: Piotr Musialek/Parham Sadeghipour Hybrid nano-coated nitinol drug-eluting stent (Hybrid-DES) and its impact on below the knee / Terumitsu Hasebe https://www.pcronline.com/Courses/EuroPCR

On May 29, 2024, at 14:40 (local time in Germany), Dr. Hasebe will be speaking at LINC 2024, the world's leading conference in the field of Interventional Radiology, to present the latest data on the stent delivery system currently under development. May 29, Wednesday / 14:30 – 15:30 CEST　SPEAKERS CORNER UPDATE ON LATEST DATA AND ONGOING TRIALS: NEW TECHNOLOGIES FOR CLTI/BTK TREATMENT Moderators: Marianne Brodmann/Francesco Liistro Impact of a hybrid nano-coated ultrathin nitinol drug-eluting stent (Hybrid-DES) for below-the-knee atherosclerotic disease: 2024 update / Terumitsu Hasebe https://www.leipzig-interventional-course.com/